From General to Personalized Care: GE HealthCare is Focused on Disease Detection and More Holistic and Effective Treatment Options
The company will showcase its latest innovative solutions to enable rapid diagnosis, Theranostics, and precision…
News
Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse Model
Data presented at the American Diabetes Association 83rd Scientific Sessions PHILADELPHIA, June 24, 2023 (GLOBE…
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
– Data Presented During Oral Session at EASL 2023 Demonstrate Fazirsiran’s Promising Impact on Key…
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 as Therapies for Chronic Hepatitis B and Hepatitis D
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection…
89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat,…
Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted…
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext…
SourceLess Brings Its Vision to ICT Spring 2023 Global Tech Conference
Luxembourg, Jun 24, 2023 – (ACN Newswire) – SourceLess, a groundbreaking technology company, announces its…
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment
Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an…
Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
– Once-weekly administration of CT-388 delivers clinically meaningful weight loss and metabolic control with a…
XORTX Reminds Shareholders to Vote ahead of the Proxy Voting Deadline for the Company’s Upcoming Annual and Special Meeting of Shareholders
The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary…
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development
First late-stage study will be a Phase 2b dose optimization study, with extension to run…
XOMA Added to the Russell 2000® and Russell 3000® Indexes
EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) — XOMA Corporation (NASDAQ: XOMA), the biotech royalty…
Kane Biotech Announces Issuance of Restricted Share Units
WINNIPEG, Manitoba, June 23, 2023 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company”…
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
Press Release No. 5 / 2023 Data shows nearly 19% weight loss in people with…
Biosenta Announces Entering Into of Agreement to Terminate Joint Venture
TORONTO, June 23, 2023 (GLOBE NEWSWIRE) — Biosenta Inc. (the “Company” or “Biosenta”) (CSE: ZRO)…
Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ENOB). Enochian BioSciences Inc., a company…
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023
ERYTECH announces the approval of the merger with Pherecydes and reports the results of…
AC Immune Holds Annual General Meeting of Shareholders
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by…
Cronos Group Inc. Announces Results of 2023 Annual Meeting of Shareholders
TORONTO, June 23, 2023 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or…